SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Boston Scientific Corporation (BSX-PA) trades at a trailing P/E of 63.0. Trailing earnings yield is 1.59%. PEG 1.14.
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 63.0).
- PEG Ratio 1.14 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 1.59% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
Overall SharesGrow Score: 76/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BSX-PA
Valuation Multiples
P/E (TTM)63.0
Forward P/EN/A
PEG Ratio1.14
Forward PEGN/A
P/B Ratio0.00
P/S Ratio9.10
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.94
Book Value / Share$0.00
Revenue / Share$13.43
FCF / Share$0.00
Yields & Fair Value
Earnings Yield1.59%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.25 |
$8.39B |
$347M |
4.1% |
| 2017 |
$0.07 |
$9.05B |
$104M |
1.1% |
| 2018 |
$1.19 |
$9.82B |
$1.67B |
17% |
| 2019 |
$3.33 |
$10.74B |
$4.7B |
43.8% |
| 2020 |
$-0.10 |
$9.91B |
$-140M |
-1.4% |
| 2021 |
$0.69 |
$11.89B |
$1.04B |
8.8% |
| 2022 |
$0.45 |
$12.68B |
$698M |
5.5% |
| 2023 |
$1.07 |
$14.24B |
$1.59B |
11.2% |
| 2024 |
$1.25 |
$16.75B |
$1.85B |
11.1% |
| 2025 |
$1.94 |
$20.07B |
$2.89B |
14.4% |
